... superior stem cell-based in vitro testing could save the pharmaceutical industry untold amounts of money, while helping ensure safer drugs get to market.
Atlanta, GA (PRWEB) July 20, 2012
MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCBB: VSTA). VistaGen Therapeutics is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of promising drug candidates that have been discontinued during preclinical development ("put on the shelf") due to safety concerns.
Yesterday, Seeking Alpha published the following blog featuring VSTA: http://seekingalpha.com/instablog/783255-missionir/871671-vistagen-therapeutics-vsta-to-revolutionize-drug-development-and-save-big-pharma-hundreds-of-millions-by-putting-humans-first
The blog, titled “VistaGen Therapeutics (VSTA) To Revolutionize Drug Development And Save Big Pharma Hundreds Of Millions By Putting Humans First,” provides a comprehensive overview of the company and its Human Clinical Trials in a Test Tube technology. VistaGen's drug rescue goal is to build on substantial prior investment by major pharmaceutical companies to generate new chemical variants of once-promising small molecule drug candidates that the pharmaceutical companies have put on hold during preclinical or early clinical trials due to heart or liver toxicity. In other words, the drug candidates were effective but had some toxic side effects.
VistaGen's pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, is based on carefully controlled differentiation of human pluripotent stem cells into multiple types of highly functional, mature human cells which then can be used in new generation bioassay systems for superior predictive toxicology testing, enabling better, more efficient drug rescue and development decision making. VistaGen's Human Clinical Trials in a Test Tube platform performs its check for toxicity with much greater flexibility, speed, and precision than other in vitro assay systems and animal testing currently in use by the pharmaceutical industry.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.